Skip to main content

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting

- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS® gene editing therapies

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that four abstracts, including one from a research and license collaboration, were accepted by the American Society of Gene & Cell Therapy (ASGCT) and will be presented as posters and oral presentations at the upcoming annual meeting on May 16-19, 2022 at the Walter E. Washington Convention Center in Washington, D.C.

Details for the poster and oral presentations can be accessed on the ASGCT website at

Oral Presentations:

Title: Targeting the Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo

Date and Time: Tuesday, May 17, 2022, 3:45 PM – 4:00 PM

Session Title: Gene Editing in Cancer and Complex Diseases

Location: Hall E

Abstract #: 447

Title: AAV-Meganuclease-Mediated Gene Targeting Achieves Efficient and Sustained Transduction in Newborn and Infant Macaque Liver1

Date and Time: Wednesday, May 18, 2022, 3:00 PM – 3:15 PM

Session Title: Presidential Symposium and Presentation of Top Abstracts

Location: Hall E

Abstract #: 811

Poster Presentations:

Title: Optimization of Hydroxyacid Oxidase 1 (HAO1) Targeting ARCUS Nucleases for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Date and Time: Monday, May 16, 2022, 5:30 PM - 6:30 PM

Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases I

Location & Poster Board Number: Hall D, M-120

Abstract #: 239

Title: ARCUS Gene Editing to Eliminate MELAS-associated m.3243A>G Mutant Mitochondrial DNA

Date and Time: Tuesday, May 17, 2022, 5:30 PM - 6:30 PM

Session Title: Gene Targeting and Gene Correction II

Location & Poster Board Number: Hall D, Tu-66

Abstract #: 561

1 University of Pennsylvania’s Gene Therapy Program presentation sponsored by iECURE.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit

$DTIL announced that four abstracts with #ARCUS genome editing will be presented as posters and oral presentations at the upcoming #ASGCT22 meeting


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.